Wisner and colleagues found that neither antenatal major depression nor SSRI exposure was significantly associated with any of the infant measurements they assessed. "Consideration of the impact of both antenatal SSRI and depression exposures on fetal and infant growth is an understudied component of the risk-benefit decision process for developing treamtent plans for depressed pregnancy women," they said.
“Does Fetal Exposure to SSRIs or Maternal Depression Impact Infant Growth?” is posted here. To read more about SSRI use during pregnancy, see Psychiatric News here and here.
(Image: BlueOrange Studio/shutterstock.com)